9 July 2026
The Investor Nature Engagement Brief series provides practical guidance for investors engaging with the eight high-impact sectors identified by Nature Action 100. Each brief supports effective investor-company engagement to help drive positive outcomes for nature.
This brief focuses on the Biotech & Pharmaceutical sector.
As a sector with significant impacts on biodiversity, the Pharmaceutical sector accounts for approximately 4% of the overall potential biodiversity impact from companies in the MSCI World Index. Informed investor engagement is essential to reducing impacts on land, water, emissions and waste and supporting a more sustainable sector transition.
This brief includes:
- Insights into the sector’s impacts and dependencies on nature, including key biodiversity risks
- Practical guidance on company actions that support alignment with the Global Biodiversity Framework (GBF)
- Ready-to-use engagement questions to help investors structure conversations with companies
- Curated tools, frameworks and resources to support effective nature-related engagement
Access the brief
Previously available exclusively to FfB Members and Nature Action 100 investors, the Investor Nature Engagement Brief series is now publicly available.
Explore the Investor Nature Engagement Brief Series
Interested in accessing exclusive member resources? Learn more about joining the Finance for Biodiversity Foundation community.